Page last checked 2026-08-13

Copper-binding tripeptide complex (research compound) · safety

AHK-Cu side effects

No controlled human trial has published a side-effect rate or safety profile for AHK-Cu. Here is what is actually known instead, and what that gap does and does not tell you.

AHK-Cu is three amino acids holding a copper ion. It differs from the better-known GHK-Cu by a single amino acid, and the two get confused constantly. It is sold mainly for hair — thicker growth, less shedding — as powder for injection or in scalp serums.

One study of it exists in the indexed literature, published in 2007. It treated human hair follicles kept alive in a dish, not people. The follicles grew longer, and the cell-death finding the authors chased was not statistically significant. No trial registry lists it.

No completed controlled human trial has shown which dose works for AHK-Cu. There is no study-backed human dosing program to publish. Animal quantities are not converted into a human recommendation.

no human dose shown to work

Further down: when to get medical help · questions

Medically reviewed by Jennifer Montecillo, MD · non-practicing medical reviewerReviewed 2026-08-13

At a glance

Common reactions listed

None published

Serious reactions listed

None published

Boxed warning

No label exists

Strongest source

no human dose shown to work

Nothing measured is not the same as nothing to find — the section below is about that difference.

When to seek medical care

Because no controlled human safety profile has been published for this compound, there is no evidence-based list of warning signs specific to it. That removes the early warning, not the risk. Any new, severe or lasting symptom belongs with a clinician. Tell them exactly what was taken.

EmergencySome symptoms should not wait for an appointment. Call emergency services (911 in the US) if they are severe, getting worse fast, or involve trouble breathing, chest pain, fainting or confusion.

3Read deeperTiming, evidence limits, and product context

Why there is no AHK-Cu side-effect profile here

There is no side-effect table on this page because there is no controlled human safety profile to build one from — and an empty table is more honest than a plausible one.

A published side-effect profile is not a summary of what people have noticed. It is the output of a specific process: a controlled trial enrolls a defined group and records every event, whether or not it looks related. It compares those rates against a control group, then publishes the result against a plan registered before the first dose. Where that process has not produced a profile, the output does not exist. Nothing stands in for it — not seller literature, not clinic protocols, not forum threads.

So the absence says something about the evidence, not about the compound. A profile nobody has measured is not a clean profile; it is an unmeasured one. Those two get confused constantly, and the confusion always runs in the direction that flatters the compound.

It is worth being blunt about the asymmetry. Rare and serious reactions are exactly the ones that scattered, self-reported experience is worst at catching. They are uncommon by definition, they can take time to appear, and they are easy to blame on something else.

The people who get them are also the least likely to come back and post an update. What shows up first in an unstudied compound is the mild and the immediate. That is a fact about how the reports get collected, not evidence about the compound.

The missing profile takes the rest of the scaffolding with it. With no approved label there is no list of who should avoid it, no documented interactions and no monitoring plan. There is no ceiling dose, and no channel carrying reports back to a regulator. Anyone taking an unapproved compound is outside all of those at once — and silence from a system that does not exist is not reassurance.

Nobody has taken AHK-Cu. The one study kept the tissue in a dish.

There is a single indexed study of this molecule and it never involved a patient. It removed hair follicles, kept them alive in a bath, and watched what happened. Everything anyone knows about this peptide in a human context comes from that arrangement.

Tissue in a bath cannot report a side effect

A follicle taken out of the scalp has no bloodstream, no liver and no immune system attached to it. Those are the systems a side effect happens in.

So the study could measure whether hairs got longer and whether cells divided. It had no way to notice a headache, a rash or a change in a blood count, because there was nobody there to have one.

The phrase that misleads is human hair follicles. Repeated without the words in a dish beside it, it reads as though people were treated. They were not.

Even the finding it went looking for did not hold

The authors set out to show fewer cells dying under treatment. Their own abstract records that the reduction was not statistically significant.

The results that did separate were indirect ones: markers of the machinery cells use to decide whether to die. Those describe a mechanism rather than an outcome.

That is worth stating plainly on a safety page. The single study behind this compound partly showed one process in tissue, once, almost twenty years ago.

The copper is a separate question nobody has asked

This is not only a peptide. It carries a metal, and the metal does not clear the way the peptide does.

The body regulates copper tightly, so the risk from exceeding that regulation is a different kind from the risk of a peptide that is simply broken down. Repeated injection is where such a question would arise.

Nothing has been measured about it here, in anyone. So the answer is not reassuring and it is not alarming. It is absent.

Nothing is watching, because there is nothing to watch

Reactions to approved drugs reach a regulator because a prescriber, a pharmacist or a manufacturer is obliged to pass them on. None of those exists here.

The result is not a clean safety record. It is an empty one, and an empty record is what you would expect whether the compound is harmless or not.

Anyone who did react to this would have nowhere to report it and nobody counting. Silence from a system nobody built is not evidence of anything.

What the absence does and does not mean

Four readings of an empty safety record go around. Each one turns a missing measurement into reassurance.

The claim	What the evidence shows
Nothing serious has been reported.	Nothing has been systematically collected. A report needs a system that receives it, strips out duplicates and counts it. For an unapproved compound there is no such system, so silence is what you would get either way.
The studies look clean.	The published work is overwhelmingly in animals or too small and uncontrolled to produce a safety rate. Animal findings do not carry over to people at human doses over human timescales, and uncontrolled exposure supplies no comparison group or denominator.
People have used it for years.	Informal use is not monitoring. Years of unmeasured use produce familiarity and confidence. They do not produce a denominator, a comparison group, or a rate.
People seem to handle it well.	How well people handle a compound is measured against a control group. Without that comparison, the claim is only the writer’s impression.

No human safety profile has been published for this compound. If that changes, the results should be reported with the study size, comparison group and citation—not filled in with assumptions.

Common questions

Does AHK-Cu have known side effects?

No controlled human study has published a side-effect rate or safety profile. That describes the missing evidence, not the compound: unmeasured does not mean safe.

Is AHK-Cu safe?

The published human evidence cannot answer that either way. Reliable safety estimates need systematic collection, a total number treated and a comparison group; none is available here.

What should someone do about symptoms after taking an unapproved compound?

Take the symptom to a clinician, and say exactly what was taken, how much and for how long. Clinicians assess symptoms without needing an approved label to exist, and leaving out the detail removes the one piece of context that changes what they look for.

The schedule these reactions were recorded against, the comparisons, and the sourcing rules behind every grade on this page.

AHK-Cu research, dosing, and approval status

No regulator has approved AHK-Cu; the guide separates human studies from reported use.

Work out the AHK-Cu draw in syringe units

Vial sizes 10 mg for AHK-Cu, each with its own concentration.

Take the AHK-Cu arithmetic to any other vial

Concentration, units per draw and draws per vial, including AHK-Cu

AHK-Cu in the regulatory changelog

A proceeding with no published outcome is entered as exactly that, including AHK-Cu

Where AHK-Cu sits among the source-checked pages

See the strongest source available for every compound, with AHK-Cu as context

What a source must satisfy to appear on AHK-Cu

Every figure ties to a primary source, or it does not ship, including AHK-Cu